TTD | Drug: D0F3OM

Drug General Information
Drug ID	D0F3OM
Former ID	DNC006931
Drug Name	2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol
Drug Type	Small molecular drug
Indication	Discovery agent		Investigative	[528490]
Formula	C9H10N6O
Canonical SMILES	C1=CC(=NNC2=C(NN=C2N)N)C(=O)C=C1
InChI	1S/C9H10N6O/c10-8-7(9(11)15-14-8)13-12-5-3-1-2-4-6(5)16/h1-4,13H,(H5,10,11,14,15)/b12-5+
InChIKey	UJKRKBDYVKFKKQ-LFYBBSHMSA-N
PubChem Compound ID	44417638
Target and Pathway
Target(s)	G1/S-specific cyclin E1	Target Info	Inhibitor	[528490]
Target(s)	Cell division protein kinase 2	Target Info	Inhibitor	[528490]
KEGG Pathway	Cell cycle
	Oocyte meiosis
	p53 signaling pathway
	PI3K-Akt signaling pathway
	Hepatitis B
	Measles
	Pathways in cancer
	Viral carcinogenesis
	MicroRNAs in cancer
	Prostate cancer
	Small cell lung cancerhsa04068:FoxO signaling pathway
	Progesterone-mediated oocyte maturation
	Herpes simplex infection
	Epstein-Barr virus infection
	Small cell lung cancer
NetPath Pathway	IL2 Signaling Pathway
NetPath Pathway	TCR Signaling PathwayNetPath_11:TCR Signaling Pathway
PANTHER Pathway	Cell cycle
	Parkinson disease
	p53 pathway
	p53 pathway feedback loops 2P00059:p53 pathway
	p53 pathway feedback loops 2
Pathway Interaction Database	Signaling events mediated by PRL
	E2F transcription factor network
	mTOR signaling pathway
	FOXM1 transcription factor network
	BARD1 signaling events
	PLK3 signaling events
	Regulation of retinoblastoma proteinsmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
	p73 transcription factor network
	ATR signaling pathway
	IL2-mediated signaling events
	FoxO family signaling
	p53 pathway
	Regulation of retinoblastoma protein
Reactome	E2F mediated regulation of DNA replication
	G0 and Early G1
	SCF(Skp2)-mediated degradation of p27/p21
	DNA Damage/Telomere Stress Induced Senescence
	Cyclin E associated events during G1/S transition
	G1/S-Specific Transcription
	p53-Dependent G1 DNA Damage ResponseR-HSA-1538133:G0 and Early G1
	Activation of ATR in response to replication stress
	Regulation of APC/C activators between G1/S and early anaphase
	Senescence-Associated Secretory Phenotype (SASP)
	Processing of DNA double-strand break ends
	G2 Phase
	Orc1 removal from chromatin
	Cyclin A/B1 associated events during G2/M transition
	p53-Dependent G1 DNA Damage Response
	Cyclin A:Cdk2-associated events at S phase entry
	Meiotic recombination
	Factors involved in megakaryocyte development and platelet production
WikiPathways	DNA Damage Response
	ID signaling pathway
	G1 to S cell cycle control
	Retinoblastoma (RB) in Cancer
	Integrated Pancreatic Cancer Pathway
	Parkinsons Disease Pathway
	Parkin-Ubiquitin Proteasomal System pathway
	Signaling Pathways in Glioblastoma
	TSH signaling pathway
	Mitotic G1-G1/S phases
	Cell Cycle
	miRNAs involved in DNA damage response
	miRNA Regulation of DNA Damage Response
	Androgen receptor signaling pathwayWP707:DNA Damage Response
	DNA Replication
	M/G1 Transition
	S Phase
	Meiotic Recombination
	Aryl Hydrocarbon Receptor
	ATM Signaling Pathway
	Spinal Cord Injury
	Oncostatin M Signaling Pathway
	Prostate Cancer
	Integrated Breast Cancer Pathway
	Integrated Cancer pathway
	Synthesis of DNA
	Regulation of DNA replication
	Mitotic G2-G2/M phases
	Factors involved in megakaryocyte development and platelet production
	APC/C-mediated degradation of cell cycle proteins
	Cell Cycle Checkpoints
References
Ref 528490	J Med Chem. 2006 Nov 2;49(22):6500-9.4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
Ref 528490	J Med Chem. 2006 Nov 2;49(22):6500-9.4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.

Drug Information